The drugmaker presented multiple posters of data for the recently reapproved BCMA-targeting antibody-drug conjugate at the just concluded ASH meeting.
Arcus is ending development of its TIGIT-targeted antibody domvanalimab after it was determined a Phase III study would not show a survival benefit in gastrointestinal cancers.
The Switzerland-based group’s alpha-synuclein-targeted immunotherapy shows promise in slowing progression of the degenerative brain condition.
Having worked in stealth on its predictive computational R&D models, PsiThera has emerged to develop oral versions of blockbuster drug targets in inflammation and immunology.
Lupeng's BTK inhibitor rocbrutinib has shown an 80.0% ORR in a Phase I trial in patients who had received a covalent or non-covalent BTK inhibitor plus BCL-2 inhibitor, setting the stage for a comparative trial, possibly with Jaypirca.
Now in their 21st year, the Scrip Awards celebrated biopharma successes at the 2025 ceremony in London’s Mayfair, where AstraZeneca and Noubar Afeyan took home the top prizes.
Triple agonist retatrutide yielded 28.7% weight loss at 68 weeks, besting Zepbound’s Phase III data, while also showing benefit in knee osteoarthritis pain.
Subsidiary Pulmovant plans to report Phase II data in pulmonary hypertension associated with interstitial lung disease in 2026, one of several programs highlighted during an investor event.
J&J's late-breaking Phase III MajesTEC-3 data at the American Society of Hematology meeting highlighted curative potential for the bispecific T-cell engager in multiple myeloma.
FOPO Edition: Capitalizing on positive data, eight drug developers priced follow-on public offerings that brought in $3.2bn, including $650m each for Terns and Structure plus $602m for Kymera.
Pfizer’s Phase III data show an 8.6-month increase in progression-free survival for Tukysa as first-line maintenance treatment of HER2+ breast cancer, a setting where the standard of care hasn’t changed since 2012.
The selective estrogen receptor degrader reduced the risk of invasive disease recurrence or death by 30% in ER-positive early stage breast cancer.
After a solid but modest launch in acute lymphoblastic leukemia, Autolus sees an opportunity for its CAR-T in autoimmune disease, starting with lupus nephritis.
To develop bispecific, dual-payload antibody-drug conjugates, Phrontline Biopharma’s strategy is to tune the activity of each payload to a similar level and engineer both toxins to fit within a branched linker, its CEO tells Scrip in an interview.
Novartis presented Phase III results for anti-BAFF/ADCC antibody ianalumab in the second-line treatment of immune thrombocytopenia but will wait for first-line data to file for approvals in 2027.
Interim Phase II data in TNBC is promising for the competitive class of medicines targeting PD-L1 and VEGF.
WVE-007 could be a "powerful disruptor" to the existing obesity market, says the company, which is set to raise $250m to fund its Phase II studies.
Early atopic dermatitis data on the oral STAT6 degrader helps the US firm’s hopes of matching the Sanofi and Regeneron injectable blockbuster on efficacy.
The company presented data on four patients as a late-breaking abstract at the American Society of Hematology meeting.
Data from the Phase III BRUIN CLL-313 trial presented at ASH showed clear superiority for the non-covalent BTK inhibitor as a single agent compared with bendamustine/rituximab.